Oncology Programs

Need Information?


LADR™ Technology Platform

Our innovative LADR™ (Linker Activated Drug Release) technology employs a broad portfolio of novel linker molecules that selectively bind to circulating albumin and have the ability to be linked to a wide variety of anti-cancer payloads. Our research efforts currently center on creating new molecules from the combination of ultra-high potency cytotoxic payloads with tunable linkers. The molecules that we are currently evaluating concentrate at the tumor site providing targeted delivery of the chemotherapeutic payloads.

View 2016 AACR Annual Meeting LADR™ Poster (PDF)